| 2021-09-13 | +38.4% | legal | SEC EDGAR | RGNX 8-K: 1.01, 7.01 (SEC Filing) |
| 2021-10-01 | -22.8% | legal | SEC EDGAR | RGNX 8-K: 7.01, 8.01 (SEC Filing) |
| 2024-11-06 | +22.2% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2026-01-27 | -20.9% | legal | Seeking Alpha | REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away |
| 2026-01-27 | -20.9% | legal | Seeking Alpha | REGENXBIO: Key FDA Decision On Hunter Syndrome Just Weeks Away (NASDAQ:RGNX) - Seeking Alpha |
| 2026-03-06 | +19.5% | news | Seeking Alpha | Assessing Where Regenxbio Stands After FY25 Results |
| 2026-03-06 | +19.5% | news | Seeking Alpha | Assessing Where Regenxbio Stands After FY25 Results (NASDAQ:RGNX) - Seeking Alpha |
| 2026-02-10 | -17.3% | legal | Seeking Alpha | Regenxbio stock drops on FDA setback for RGX-121 gene therapy |
| 2026-02-10 | -17.3% | legal | SEC EDGAR | RGNX 8-K: 7.01, 8.01 (SEC Filing) |
| 2026-02-10 | -17.3% | legal | Seeking Alpha | Regenxbio stock drops on FDA setback for RGX-121 gene therapy (RGNX:NASDAQ) - Seeking Alpha |
| 2026-02-10 | -17.3% | analyst | Investing.com | Regenxbio stock price target lowered by Goldman Sachs on RGX-121 setback - Investing.com |
| 2026-02-10 | -17.3% | news | Benzinga | Why Is REGENXBIO Stock Falling Today? - Regenxbio (NASDAQ:RGNX) - Benzinga |
| 2026-02-10 | -17.3% | analyst | GuruFocus | Morgan Stanley Lowers Price Target for RGNX to $18 | RGNX Stock News - GuruFocus |
| 2026-02-10 | -17.3% | analyst | GuruFocus | Regenxbio (RGNX) Analyst Rating Update: Price Target Lowered by HC Wainwright | RGNX Stock News - GuruFocus |
| 2021-11-12 | -16.3% | legal | SEC EDGAR | RGNX 8-K: 7.01, 8.01 (SEC Filing) |
| 2021-11-15 | -16.2% | legal | SEC EDGAR | RGNX 8-K: 1.01 (SEC Filing) |
| 2025-10-08 | +15.5% | news | TradingKey | RGNX|Regenxbio Inc|Price:9.470|Chg%:-0.02 - TradingKey |
| 2022-11-03 | -14.9% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2026-02-09 | -14.5% | legal | Investing.com | REGENXBIO stock falls after FDA rejects gene therapy for Hunter syndrome - Investing.com |
| 2026-02-09 | -14.5% | legal | Stock Titan | FDA withholds approval for REGENXBIO gene therapy for Hunter syndrome - Stock Titan |
| 2026-02-09 | -14.5% | legal | Stocktwits | Regenxbio Stock Still Has Over 300% Upside Despite FDA Pushback On Hunter Syndrome Drug: Clear Street - Stocktwits |
| 2026-02-09 | -14.5% | legal | Stock Titan | FDA issues Complete Response Letter on REGENXBIO (RGNX) RGX-121 gene therapy BLA - Stock Titan |
| 2026-03-09 | +13.7% | news | Seeking Alpha | REGENXBIO Inc. (RGNX) Presents at Leerink Global Healthcare Conference 2026 Transcript |
| 2026-03-09 | +13.7% | legal | Seeking Alpha | Biotech firm stocks rise on FDA vaccine heads exit |
| 2026-03-09 | +13.7% | analyst | Investing.com | H.C. Wainwright cuts Regenxbio stock price target to $30 - Investing.com |
| 2026-03-09 | +13.7% | analyst | GuruFocus | Regenxbio (RGNX): HC Wainwright Maintains Rating, Lowers Price T - GuruFocus |
| 2024-01-07 | -13.6% | analyst | eToro | RGNX Stock Price | Analyst Target 31.00 & Consensus - eToro |
| 2022-05-04 | -13.6% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2026-01-28 | -13.3% | legal | Seeking Alpha | REGENXBIO falls after FDA clinical hold on gene therapies |
| 2026-01-28 | -13.3% | legal | SEC EDGAR | RGNX 8-K: 8.01 and (SEC Filing) |
| 2026-01-28 | -13.3% | legal | NewMediaWire | Kaplan Fox Alerts Investors of REGENXBIO Inc. (RGNX) to an Investigation of Possible Securities Law Violations - NewMediaWire |
| 2026-01-28 | -13.3% | legal | Seeking Alpha | REGENXBIO falls after FDA clinical hold on gene therapies - Seeking Alpha |
| 2026-01-28 | -13.3% | legal | Stocktwits | RGNX Stock Is Falling Today — What Is The FDA Update On REGENXBIO's Gene Therapy? - Stocktwits |
| 2026-01-28 | -13.3% | analyst | Investing.com | Stifel reiterates Buy rating on Regenxbio stock amid clinical hold - Investing.com |
| 2026-01-28 | -13.3% | legal | Benzinga | FDA Clinical Hold Knocks REGENXBIO Stock - Benzinga |
| 2026-01-28 | -13.3% | legal | GlobeNewswire | INVESTOR ALERT: Investigation of REGENXBIO Inc. (RGNX) by Holzer & Holzer, LLC - GlobeNewswire |
| 2025-06-06 | +12.9% | news | Seeking Alpha | Regenxbio's RGX-121 Could Become The New Standard Of Care In Hunter Syndrome - Seeking Alpha |
| 2025-05-19 | +12.7% | legal | SEC EDGAR | RGNX 8-K: 1.01, 2.03, 7.01 (SEC Filing) |
| 2022-03-01 | +10.8% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2023-02-28 | +10.8% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2026-03-10 | -9.3% | news | PR Newswire | Investors who lost money on REGENXBIO Inc.(RGNX) should contact The Gross Law Firm about pending Class Action - RGNX - PR Newswire |
| 2023-05-05 | -9.2% | analyst | Zacks Investment Research | What is the current Price Target and Forecast for REGENXBIO (RGNX) - Zacks Investment Research |
| 2024-02-27 | +8.5% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2025-08-18 | -8.4% | legal | Seeking Alpha | Regenxbio says FDA extends review date for Hunter syndrome drug |
| 2025-08-18 | -8.4% | legal | SEC EDGAR | RGNX 8-K: 8.01 and (SEC Filing) |
| 2026-01-14 | -8.4% | news | Seeking Alpha | REGENXBIO Inc. (RGNX) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript |
| 2024-05-08 | -8.1% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2022-08-03 | +7.7% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2026-01-30 | -7.3% | news | Yahoo Finance | Regenxbio (RGNX) Soars 5.4%: Is Further Upside Left in the Stock? - Yahoo Finance |
| 2023-11-01 | +7.1% | news | Seeking Alpha | Stifel starts Regenxbio at buy; cites broad platform, deep portfolio (RGNX) - Seeking Alpha |
| 2023-08-02 | -7.0% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2026-02-26 | +7.0% | earnings | Yahoo Finance | Regenxbio (RGNX) Expected to Beat Earnings Estimates: Can the Stock Move Higher? - Yahoo Finance |
| 2026-03-25 | +7.0% | legal | Investor's Business Daily | Denali Jumps, Pulling Regenxbio Higher, On Early FDA Approval |
| 2026-03-25 | +7.0% | news | Pharma Voice | Mixed signals cloud the orphan drug market |
| 2026-03-11 | -6.6% | news | MT Newswires | Regenxbio Reports 'Positive' Interim Data in Duchenne Trial |
| 2026-03-11 | -6.6% | news | PR Newswire | REGENXBIO REPORTS NEW POSITIVE INTERIM DATA FROM PHASE I/II AFFINITY DUCHENNE® TRIAL OF RGX-202 |
| 2026-03-11 | -6.6% | news | Stock Titan | Early Duchenne gene therapy trial boosts movement, heart stability - Stock Titan |
| 2026-03-11 | -6.6% | news | PR Newswire | Investors who lost money on REGENXBIO Inc.(RGNX) should contact Levi & Korsinsky about pending Class Action - RGNX - PR Newswire |
| 2026-04-23 | -6.6% | earnings | Cổng thông tin điện tử tỉnh Tây Ninh | RGNX (REGENXBIO Inc.) reports wider than expected Q4 2025 loss while shares climb on positive investor sentiment. - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-03-12 | -6.6% | news | Seeking Alpha | REGENXBIO Inc. (RGNX) Presents at 2026 MDA Clinical & Scientific Conference - Slideshow |
| 2026-03-12 | -6.6% | news | Investing.com | Pakola Steve, Regenxbio CMO, sells $53k in RGNX stock - Investing.com |
| 2025-08-08 | -6.2% | news | Seeking Alpha | Regenxbio accelerates RGX-202 pivotal enrollment to October 2025 as topline data targeted for early 2026 |
| 2025-08-08 | -6.2% | earnings | Seeking Alpha | REGENXBIO Inc. (RGNX) Q2 2025 Earnings Call Transcript |
| 2022-02-14 | +6.1% | legal | SEC EDGAR | RGNX 8-K: 7.01, 8.01 (SEC Filing) |
| 2024-06-13 | -5.9% | legal | SEC EDGAR | RGNX 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-03-04 | +5.7% | legal | SEC EDGAR | RGNX 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-10-10 | -5.6% | executive | Investing.com | Regenxbio CEO Simpson Curran sells $262,634 in stock - Investing.com |
| 2026-01-19 | +5.6% | news | Yahoo Finance | REGENXBIO Inc. (RGNX): A Bull Case Theory - Yahoo Finance |
| 2021-10-12 | +5.5% | legal | SEC EDGAR | RGNX 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-08-07 | -5.3% | legal | SEC EDGAR | RGNX 8-K: 1.01, 2.02, 7.01 (SEC Filing) |
| 2026-02-20 | -5.3% | M&A | Seeking Alpha | Regenxbio dealt win by appeals court in patent spat with Sarepta |
| 2026-02-20 | -5.3% | legal | DirectorsTalk Interviews | REGENXBIO Inc. (RGNX) Stock Analysis: Examining a 238% Potential Upside in the Biotech Sector - DirectorsTalk Interviews |
| 2026-02-20 | -5.3% | legal | GlobeNewswire | RGNX Stockholder Alert: Robbins LLP Remind Investors of the Class Action Lawsuit Against REGENXBIO, Inc. - GlobeNewswire |
| 2026-02-20 | -5.3% | M&A | Seeking Alpha | Regenxbio dealt win by appeals court in patent spat with Sarepta - Seeking Alpha |
| 2024-08-01 | -5.2% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2022-02-09 | -5.2% | legal | SEC EDGAR | RGNX 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-01-14 | +5.1% | legal | SEC EDGAR | RGNX 8-K: 1.01, 7.01 (SEC Filing) |
| 2025-05-12 | +4.8% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2025-05-12 | +4.8% | news | Stock Titan | REGENXBIO Reports First Quarter 2025 Financial Results and Recent Operational Highlights - Stock Titan |
| 2023-01-10 | +4.4% | legal | SEC EDGAR | RGNX 8-K: 5.02 and (SEC Filing) |
| 2024-03-11 | -4.4% | legal | SEC EDGAR | RGNX 8-K: 8.01 and (SEC Filing) |
| 2021-05-05 | +4.0% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2024-08-06 | -4.0% | legal | SEC EDGAR | RGNX 8-K: 5.02 (SEC Filing) |
| 2026-02-13 | -3.9% | legal | Seeking Alpha | Regenxbio: Cautiously Bullish After FDA Setbacks |
| 2026-02-13 | -3.9% | legal | Seeking Alpha | REGENXBIO: Cautiously Bullish After FDA Setbacks (NASDAQ:RGNX) - Seeking Alpha |
| 2026-03-27 | -3.9% | news | Stock Titan | Vanguard (RGNX) disaggregates holdings; reports 0 shares after realignment - Stock Titan |
| 2021-09-07 | -3.8% | legal | SEC EDGAR | RGNX 8-K: 5.02 and (SEC Filing) |
| 2023-05-03 | +3.5% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2026-03-05 | -3.5% | news | Seeking Alpha | Regenxbio outlines 2026 Duchenne, wet AMD, and diabetic retinopathy milestones while targeting pivotal data releases |
| 2026-03-05 | -3.5% | earnings | Seeking Alpha | REGENXBIO Inc. (RGNX) Q4 2025 Earnings Call Transcript |
| 2026-03-05 | -3.5% | earnings | Seeking Alpha | Regenxbio GAAP EPS of -$1.30 misses by $0.36, revenue of $30.34M misses by $15.14M |
| 2026-03-05 | -3.5% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2026-03-05 | -3.5% | earnings | Investing.com India | Regenxbio Inc earnings missed by $0.58, revenue fell short of estimates - Investing.com India |
| 2021-11-02 | +3.4% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2025-11-09 | -3.3% | earnings | Yahoo Finance | Earnings Update: REGENXBIO Inc. (NASDAQ:RGNX) Just Reported And Analysts Are Boosting Their Estimates - Yahoo Finance |
| 2025-11-08 | -3.3% | earnings | Seeking Alpha | REGENXBIO's Late-Stage Pipeline Momentum Strengthens After Q3 Earnings Beat |
| 2025-11-08 | -3.3% | earnings | Seeking Alpha | REGENXBIO’s Late-Stage Pipeline Momentum Strengthens After Q3 Earnings Beat (NASDAQ:RGNX) - Seeking Alpha |
| 2026-01-11 | +3.2% | legal | Stock Titan | Gene therapy shows lasting gains for patients with Duchenne; FDA date set - Stock Titan |
| 2026-01-12 | +3.2% | news | Seeking Alpha | Regenxbio rises on data for Duchenne muscular dystrophy candidate |
| 2026-01-12 | +3.2% | news | RTTNews | REGENXBIO Stock Hits New High On Duchenne Trial Data - Will 2026 Be A Transformative Year? - RTTNews |
| 2023-07-13 | -3.1% | news | Quiver Quantitative | RGNX | REGENXBIO Inc. Stock Data, Price & News - Quiver Quantitative |
| 2022-06-07 | +3.0% | legal | SEC EDGAR | RGNX 8-K: 5.02, 5.07 (SEC Filing) |
| 2023-11-08 | +3.0% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2024-12-09 | +2.7% | legal | SEC EDGAR | RGNX 8-K: 8.01 and (SEC Filing) |
| 2026-04-03 | +2.7% | news | Stock Titan | REGENXBIO (RGNX) proxy: directors, PwC ratification, option-exchange votes - Stock Titan |
| 2025-11-05 | -2.6% | earnings | Seeking Alpha | Regenxbio Q3 2025 Earnings Preview |
| 2025-09-06 | -2.6% | analyst | Seeking Alpha | Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome |
| 2025-09-06 | -2.6% | analyst | Seeking Alpha | Regenxbio: Remains A "Buy Rating" Despite BLA Review Delay Of RGX-121 For Hunter Syndrome (NASDAQ:RGNX) - Seeking Alpha |
| 2025-11-06 | -2.5% | earnings | Seeking Alpha | REGENXBIO plans top-line RGX-202 Duchenne data release in early Q2 2026 while advancing toward 2027 commercial launch |
| 2025-11-06 | -2.5% | earnings | Seeking Alpha | REGENXBIO Inc. (RGNX) Q3 2025 Earnings Call Transcript |
| 2025-11-06 | -2.5% | earnings | Seeking Alpha | Regenxbio GAAP EPS of -$1.20 beats by $0.14, revenue of $29.7M beats by $5.29M |
| 2025-11-06 | -2.5% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2025-11-12 | +2.4% | news | Seeking Alpha | REGENXBIO Inc. (RGNX) Presents at Stifel 2025 Healthcare Conference Transcript |
| 2024-03-29 | +2.4% | news | CNN | symbol__ Stock Quote Price and Forecast - CNN |
| 2025-03-26 | -2.2% | news | Seeking Alpha | 5 Reasons To Buy Regenxbio Right Now (NASDAQ:RGNX) - Seeking Alpha |
| 2025-12-15 | +2.2% | analyst | Investing.com | Leerink Partners raises Regenxbio stock price target to $20 on DMD opportunity - Investing.com |
| 2026-04-22 | -1.9% | news | Zacks | OCGN Gene Therapy Pipeline: Key 2026-27 Catalysts Ahead |
| 2026-04-22 | -1.9% | news | Zacks | Ocugen Stock Outlook: Valuation, Cash Runway and Dilution Risk |
| 2026-02-06 | -1.9% | news | simplywall.st | REGENXBIO Inc. (NASDAQ:RGNX) Looks Inexpensive After Falling 28% But Perhaps Not Attractive Enough - simplywall.st |
| 2025-07-24 | -1.9% | news | Yahoo Finance | REGENXBIO Inc. (RGNX): A Bull Case Theory - Yahoo Finance |
| 2026-01-29 | +1.9% | news | simplywall.st | Is REGENXBIO (NASDAQ:RGNX) Weighed On By Its Debt Load? - simplywall.st |
| 2026-01-29 | +1.9% | legal | MSN | RGNX stock is falling today — what is the FDA update on REGENXBIO's gene therapy? - MSN |
| 2024-07-30 | -1.8% | executive | Yahoo Finance | Insider Sale: CEO Curran Simpson Sells Shares of Regenxbio Inc (RGNX) - Yahoo Finance |
| 2021-11-09 | -1.7% | legal | SEC EDGAR | RGNX 8-K: 7.01, 8.01 (SEC Filing) |
| 2025-12-02 | +1.7% | news | Seeking Alpha | REGENXBIO Inc. (RGNX) Presents at Piper Sandler 37th Annual Healthcare Conference Transcript |
| 2025-11-26 | -1.7% | news | Seeking Alpha | Regenxbio files $300M mixed shelf offering |
| 2022-08-28 | -1.6% | analyst | TradingView | RGNX Forecast — Price Target — Prediction for 2027 - TradingView |
| 2026-04-14 | +1.5% | legal | PR Newswire | RGNX Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in REGENXBIO Inc. Securities Lawsuit -- The Gross Law Firm - PR Newswire |
| 2026-04-14 | +1.5% | legal | Stock Titan | [ARS] REGENXBIO Inc. SEC Filing - Stock Titan |
| 2026-04-14 | +1.5% | legal | PR Newswire | RGNX Deadline Today: RGRX Investors Have Opportunity to Lead REGENXBIO, Inc. Securities Fraud Lawsuit - PR Newswire |
| 2025-04-25 | -1.5% | news | Stock Titan | RGNX Stock Price, News & Analysis - Stock Titan |
| 2024-09-17 | -1.4% | legal | SEC EDGAR | RGNX 8-K: 5.02, 7.01 (SEC Filing) |
| 2025-09-08 | +1.4% | news | Seeking Alpha | REGENXBIO Inc. (RGNX) Presents At Morgan Stanley 23rd Annual Global Healthcare Conference Transcript |
| 2023-09-01 | -1.2% | legal | SEC EDGAR | RGNX 8-K: 8.01 and (SEC Filing) |
| 2021-07-16 | +1.2% | legal | SEC EDGAR | RGNX 8-K: 8.01 (SEC Filing) |
| 2023-08-10 | -1.1% | news | Seeking Alpha | Regenxbio: RGX-314 Continues Advancing With Solid Financials (NASDAQ:RGNX) - Seeking Alpha |
| 2026-02-03 | +1.0% | legal | marketscreener.com | RGNX Investors Have Opportunity to Join REGENXBIO Inc. Fraud Investigation with the Schall Law Firm - marketscreener.com |
| 2026-04-01 | +0.9% | news | Investor's Business Daily | Denali Solved A Major Challenge In Treating A Rare Genetic Disease. Now, Shares Are Flying. |
| 2022-03-25 | -0.9% | legal | SEC EDGAR | RGNX 8-K: 1.01 (SEC Filing) |
| 2025-09-05 | +0.7% | news | Seeking Alpha | REGENXBIO reports positive data from Hunter syndrome |
| 2021-09-17 | +0.6% | news | The Motley Fool | Regenxbio - RGNX - Stock Price & News - The Motley Fool |
| 2022-03-18 | +0.5% | legal | SEC EDGAR | RGNX 8-K: 5.02 (SEC Filing) |
| 2026-02-16 | +0.5% | news | marketscreener.com | Rosen Law Firm Urges REGENXBIO, Inc. (NASDAQ: RGNX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights - marketscreener.com |
| 2026-03-28 | +0.5% | news | Cổng thông tin điện tử tỉnh Tây Ninh | Should I Buy REGENXBIO (RGNX) Stock Today | Price at $8.91, Up 1.25% - Loss Prevention - Cổng thông tin điện tử tỉnh Tây Ninh |
| 2026-03-28 | +0.5% | news | Cổng thông tin điện tử Tỉnh Sơn La | Should I Buy REGENXBIO (RGNX) Stock Today | Price at $8.91, Up 1.25% - Loss Prevention - Cổng thông tin điện tử Tỉnh Sơn La |
| 2026-03-20 | +0.4% | news | Zacks | OCGN Gene-Agnostic Eye Therapy Could Shift Retinal Drug Development |
| 2026-03-20 | +0.4% | news | Zacks | Ocugen Stock Outlook: Balancing Cash Burn and Late-Stage Data |
| 2026-03-20 | +0.4% | news | Zacks | OCGN Gene Therapy Pipeline: 2026-2027 Catalysts To Watch |
| 2026-03-20 | +0.4% | legal | SEC EDGAR | RGNX 8-K: 1.01 (SEC Filing) |
| 2026-03-20 | +0.4% | legal | Stock Titan | REGENXBIO (NASDAQ: RGNX) agrees $10M settlement payment to GSK - Stock Titan |
| 2025-09-09 | +0.4% | news | Seeking Alpha | Regenxbio: Poised For Breakthrough With RGX-121 Gene Therapy In Hunter Syndrome |
| 2025-02-26 | -0.2% | news | Stock Titan | When Will REGENXBIO Reveal Its 2024 Financial Performance? Key Date for Biotech Investors - Stock Titan |
| 2025-01-15 | -0.2% | news | Seeking Alpha | Regenxbio Inc.: Why It Is Down, And When It Will Go Up Again (NASDAQ:RGNX) - Seeking Alpha |
| 2026-03-04 | +0.2% | earnings | Seeking Alpha | Regenxbio Q4 2025 Earnings Preview |
| 2026-03-04 | +0.2% | news | Stock Titan | New gene therapy data for Duchenne muscular dystrophy heads to MDA - Stock Titan |
| 2026-01-13 | -0.2% | news | Quiver Quantitative | Lobbying Update: $60,000 of REGENXBIO INC. lobbying was just disclosed | RGNX Stock News - Quiver Quantitative |
| 2025-03-13 | +0.0% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2021-08-09 | +0.0% | legal | SEC EDGAR | RGNX 8-K: 2.02 and (SEC Filing) |
| 2026-04-26 | — | earnings | MarketBeat | REGENXBIO Inc. (NASDAQ:RGNX) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat |